e-learning
resources
Berlin 2008
Monday, 06.10.2008
Improving asthma and anti-allergic therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Identifying patients with severe allergic asthma who are potentially eligible for omalizumab treatment by EU licence and NICE guidance criteria
A. Mistry, E. Watkins, M. Britton, M. Nordstrom (Surrey, United Kingdom)
Source:
Annual Congress 2008 - Improving asthma and anti-allergic therapy
Session:
Improving asthma and anti-allergic therapy
Session type:
Thematic Poster Session
Number:
2006
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Mistry, E. Watkins, M. Britton, M. Nordstrom (Surrey, United Kingdom). Identifying patients with severe allergic asthma who are potentially eligible for omalizumab treatment by EU licence and NICE guidance criteria. Eur Respir J 2008; 32: Suppl. 52, 2006
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Mepolizumab eligibility in children with severe asthma – do we need paediatric specific criteria?
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
Source: International Congress 2017 – Asthma management
Year: 2017
The application of GINA guidelines results in a reduced number of exacerbations in asthmatic patients
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009
Is mild asthma outside the guidelines?
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE)
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Are current treatment recommendations suited to elderly patients with asthma or COPD?
Source: Eur Respir Mon; 2009: 43: 267–285
Year: 2009
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Cost of asthma in patients treated with national asthma guideline in Turkey
Source: Eur Respir J 2003; 22: Suppl. 45, 481s
Year: 2003
Should patients with mild asthma be excluded from allergic rhinitis drug trials?
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
From guidelines to personalized treatment of children with asthma
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Safety of omalizumab therapy in children with allergic asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Evaluation of a diagnostic–therapeutic pathway on GINA guidelines between specialist and primary care physicians. Study and result at 1 year in children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept